||Interleukin-17F (IL-17F), Human;
||Human IL-17F is synthesized as a 153 aa precursor with a 20 aa signal sequence and a 133 aa mature region. Like IL-17A, IL-17F contains one potential site for N-linked glycosylation. IL-17A and IL-17F share 50% aa sequence identity. IL17-F homodimer is produced by an activated subset of CD4+ T cells, termed Th17. IL17-F has been shown to stimulate proliferation and activation of T-cells and PBMCs. IL-17F also regulates cartilage matrix turnover and inhibits angiogenesis.
|Amino Acid Sequence
MRKIPKVGHT FFQKPESCPP VPGGSMKLDI GIINENQRVS
PNRYPSEVVQ AQCRNLGCIN AQGKEDISMN
SVPIQQETLV VRRKHQGCSV SFQLEKVLVT
||Fully biologically active when compared to standard. The ED50 as determined by inducing IL-6 secretion of murine NIH/3T3 cells is less than 20 ng/ml, corresponding to a specific activity of > 5.0 × 104 IU/mg.
||Sterile Filtered White lyophilized (freeze-dried) powder.
||Approximately 30.1 kDa, a disulfide-linked homodimer of two 134 amino acid polypeptide chains.
||Lyophilized from a 0.2 μm filtered concentrated solution in PBS, pH 7.2, with trehalose.
||We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in 4 mM HCl to a concentration of 0.1mg/ml. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions.
||> 95 % by SDS-PAGE and HPLC analyses.
||Less than 1 EU/μg of rHuIL-17F as determined by LAL method.
||This lyophilized preparation is stable at 2-8 °C, but should be kept at -20 °C for long term storage, preferably desiccated. Upon reconstitution, the preparation is stable for up to one week at 2-8 °C. For maximal stability, apportion the reconstituted preparation into working aliquots and store at -20 °C to -70 °C. Avoid repeated freeze/thaw cycles.
Kim G, Khanal .et al Interleukin-17 induces AP-1 activity and cellular transformation via upregulation of tumor progression locus 2 activity. Carcinogenesis.